Lipid profile in patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002
Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Multidrug resistant tuberculosis in non HIV patients Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Treatment‘s side effects in MDR tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 454s Year: 2005
Characteristics of the cases with primary multidrug resistance pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
Expression of P-gP in patients with resistant tuberculosis Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
Cytokine gene polymorphisms and mycobacterium tuberculosis : from infection to pulmonary disease Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection Year: 2006
Clinical characteristic of the patients with drug resistant pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Monitoring of drug resistance of TB mycobacteria in new pulmonary TB patients Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Burden of the primary drug resistance of Mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Outcomes of patients with multidrug resistant tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Management of MDR tuberculosis Source: Short video discussion 2021 Year: 2021
Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004